The new CEO of the La Jolla Institute for Immunology ascended by lifting others
Erica Ollman Saphire brings together scientific competitors to find new antibody therapeutics for COVID-19.
Shape-shifting Ebola virus protein exploits human RNA to change shape
New study highlights VP40 as a promising therapeutic target
Erica Ollmann Saphire appointed president and CEO of La Jolla Institute for Immunology
Dr. Saphire will become La Jolla Institute’s fifth president when she formally begins her term on September 1, 2021
Leinco Technologies, Inc., and La Jolla Institute for Immunology announce license agreement to develop novel COVID-19 diagnostic tools
In addition to developing the antibodies for use in diagnostic applications based on N protein-specific antibodies, Leinco will make these antibodies commercially available as part of their extensive catalogue of research tools.
Experts torn over changing vaccine doses to speed up lagging rollout
To speed inoculations, the U.S. plans to release all available vaccine doses and open access to anyone over 65. Others suggest straying from recommended doses or intentionally delaying boosters. The best way forward remains uncertain.
Immunological memory to SARS-CoV-2 assessed for up to 8 months after infection
Erica Ollmann Saphire named Scientist of the Year by ARCS San Diego
Award recognizes Saphire's leadership in global effort against COVID-19
Lifted Up from Lockdown
3 things we know (and 3 we don’t) about Pfizer’s initial COVID-19 vaccine results
San Diego scientists and trial participants are cautiously optimistic after early reports that Pfizer’s COVID-19 vaccine is highly effective
T cells take the lead in controlling SARS-CoV-2 and reducing COVID-19 disease severity
LA JOLLA, CA—Ever since SARS-CoV-2 first appeared, researchers have been trying to understand whether sometimes the immune system does more